The FDA on Friday approved a Gilead Sciences drug developed for treating mantle cell lymphoma, paving the way for the company to commercialize its second cancer cell therapy.

Approval for the drug, brexucabtagene autoleucel (Tecartus), covers patients whose cancer has relapsed or has not responded to earlier treatments. Gilead (NASDAQ: GILD) added the therapy to its pipeline via its $12 billion acquisition of Kite Pharma in 2017, a deal headlined by Yescarta, a cell therapy that went on to win approval later that year in non-Hodgkin lymphoma. Both Yescarta and Tecartus are chimeric antigen receptor (CAR) T cell… Read more »